11 Biotechnology Stocks to Buy Now

by Portfolio Grader | July 30, 2014 10:45 am

This week, 11 biotechnology stocks are improving their overall ratings on Portfolio Grader[1]. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

Epizyme, Inc. (EPZM[2]) is bumping up its rating from a C (“hold”) to a B (“buy”) this week. In Portfolio Grader’s specific subcategories of Earnings Momentum and Sales Growth, EPZM also gets A’s. For more information, get Portfolio Grader’s complete analysis of EPZM stock[3].

Stemline Therapeutics, Inc. (STML[4]) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. For more information, get Portfolio Grader’s complete analysis of STML stock[5].

This week, Pharmacyclics, Inc.’s (PCYC[6]) ratings are up from a C last week to a B. Pharmacyclics is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis, and retinal disease. Shares of the stock have been changing hands at an unusually rapid pace, twice the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of PCYC stock[7].

This week, Acorda Therapeutics, Inc. (ACOR[8]) pushes up from a C to a B rating. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. For more information, get Portfolio Grader’s complete analysis of ACOR stock[9].

Northwest Biotherapeutics, Inc. (NWBO[10]) gets a higher grade this week, advancing from a C last week to a B. Northwest Biotherapeutics engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States. Shares of the stock have been trading at an exceptionally rapid pace, up twofold from the week prior. For more information, get Portfolio Grader’s complete analysis of NWBO stock[11].

PTC Therapeutics, Inc. (PTCT[12]) is seeing ratings go up from a C last week to a B this week. For more information, get Portfolio Grader’s complete analysis of PTCT stock[13].

This week, Cellular Biomedicine Group, Inc. (CBMG[14]) pushes up from a B to an A rating. Shares of the stock have been changing hands at an unusually rapid pace, twice the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of CBMG stock[15].

Tonix Pharmaceuticals Holding Corp. (TNXP[16]) gets a higher grade this week, advancing from a C last week to a B. Shares of the stock have been trading at an exceptionally rapid pace, up twofold from the week prior. For more information, get Portfolio Grader’s complete analysis of TNXP stock[17].

BioMarin Pharmaceutical (BMRN[18]) improves from a C to a B rating this week. BioMarin Pharmaceutical develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. For more information, get Portfolio Grader’s complete analysis of BMRN stock[19].

Seattle Genetics, Inc. (SGEN[20]) is seeing ratings go up from a C last week to a B this week. Seattle Genetics is a clinical-stage biotechnology company that is focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. For more information, get Portfolio Grader’s complete analysis of SGEN stock[21].

Amgen (AMGN[22]) earns an A this week, jumping up from last week’s grade of B. Amgen discovers, develops, manufactures, and markets medicines for serious illnesses. The stock’s dividend yield is 2.4%. For more information, get Portfolio Grader’s complete analysis of AMGN stock[23].

Louis Navellier’s proprietary Portfolio Grader[24] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[25].

Source URL: https://investorplace.com/2014/07/11-biotechnology-stocks-to-buy-now-epzm-stml-pcyc/

---